falsefalse

Emerging Therapies in the Management of HR+, HER2- Metastatic Breast Cancer - Episode 6

The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer

,

The EMERALD study showed improved progression-free survival with elacestrant compared to standard endocrine therapy in patients with ESR1 mutations who progressed on prior AI and CDK4/6 inhibitors, with the greatest benefit in those having longer duration of response to first-line therapy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: An Overview of HR+, HER2- Metastatic Breast Cancer
    EP. 2: Overview of the Treatment Landscape for HR+, HER2- Advanced or Metastatic Breast Cancer
    EP. 3: The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer
    EP. 4: Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy
    EP. 5: CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer
    Now Viewing
    EP. 6: The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer
    EP. 7: The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer
    EP. 8: Approaches to Treatment Decision-Making and Sequencing for HR+, HER2- Metastatic Breast Cancer
    EP. 9: Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer

    Related Content:

    Emerging Therapies in the Management of HR+, HER2- Metastatic Breast CancerOncLive News Network®Breast Cancer
    Sacituzumab Govitecan Plus Pembrolizumab Displays Activity in Early-Stage TNBC
    Ribociclib Benefit Is Sustained in HR+ Early Breast Cancer Regardless of Age, Menopausal Status
    Early Switch With Camizestrant Plus Continued CDK4/6 Inhibition Nearly Doubles PFS in ESR1-Mutant, ER+/HER2– Advanced Breast Cancer
    x